COVID-19 Vaccine Efficacy in patients with Blood Cancer

Not Applicable

Recruiting

• Conditions: Haematological Malignancy; Bone Marrow Transplant; COVID-19; Cancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma; Cancer - Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma; Cancer - Myeloma; Cancer - Hodgkin's; Cancer - Leukaemia - Acute leukaemia; Cancer - Leukaemia - Chronic leukaemia

• Registration Number: ACTRN12621000538842
• Lead Sponsor: Royal Brisbane and Women's Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-05-06
• Last Update Posted: 7 June 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. Greater than or equal to 18 years of age
2. Able to provide voluntary informed consent
3. Planned receipt of a COVID19 vaccine of any variety; e.g. Pfizer-BioNTech BNT162b2, AstraZeneca Oxford ChAdOx1 nCoV-19 (AZD1222), Novavax NVX-CoV2373 or ModernaTX mRNA-1273 vaccine.
- Patients who have any haematological malignancy and received treatment with a B-cell targeted therapy or who have received a bone marrow transplant may be recruited to Cohort A.
- Patients who do not have a diagnosis of a haematological malignancy or any other active cancer, and who have not received treatment with B cell depleting antibodies will be recruited to Cohort B. 50 patients will be recruited in total, 30 to Cohort A and 20 to Cohort B.

Exclusion Criteria

1. Current diagnosis of and/or treatment for a non-haematological malignancy.
2. Receipt of B cell targeted therapies for Rheumatological or other non-haematological malignancy indication
3. Unable to provide voluntary informed consent

Study & Design

• Study Type: Observational
• Study Design: Not specified